Mendus AB
IMMU
Company Profile
Business description
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals. Company Pipeline includes: Vididencel, Ilixadencel, Preclinical.
Contact
Vastra Tradgardsgatan 15
Stockholm11153
SWET: +46 87328400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
30
Stocks News & Analysis
stocks
Chart of the Week: Opportunities with wide-moat retailers
Consumer defensive names look undervalued.
stocks
New ASX share added to our best ideas
Earnings outlook is strong and the shares trade at a discount to our fair value.
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,136.60 | 15.10 | 0.17% |
| CAC 40 | 7,966.95 | 71.01 | 0.90% |
| DAX 40 | 24,113.62 | 232.90 | 0.98% |
| Dow JONES (US) | 46,441.10 | 43.21 | 0.09% |
| FTSE 100 | 9,446.43 | 96.00 | 1.03% |
| HKSE | 26,855.56 | 232.68 | 0.87% |
| NASDAQ | 22,755.16 | 95.15 | 0.42% |
| Nikkei 225 | 44,550.85 | 381.78 | -0.85% |
| NZX 50 Index | 13,418.01 | 15.98 | -0.12% |
| S&P 500 | 6,711.20 | 22.74 | 0.34% |
| S&P/ASX 200 | 8,845.70 | 12.30 | 0.14% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |